Dr. Reddy's Laboratories Limited RDY
NYSE
| 09/30/2026 | 06/30/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 6.24% | 3.95% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 6.24% | 3.95% | |||
| Cost of Revenue | -4.92% | 0.76% | |||
| Gross Profit | 19.07% | 7.87% | |||
| SG&A Expenses | -3.67% | 0.50% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -81.39% | 33.37% | |||
| Total Operating Expenses | -5.38% | 1.09% | |||
| Operating Income | 268.01% | 186.58% | |||
| Income Before Tax | 119.69% | 168.68% | |||
| Income Tax Expenses | 163.83% | 632.88% | |||
| Earnings from Continuing Operations | 107.73% | 90.89% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 31.85% | 2,206.41% | |||
| Net Income | 106.24% | 95.06% | |||
| EBIT | 268.01% | 186.58% | |||
| EBITDA | 102.62% | 69.32% | |||
| EPS Basic | 106.39% | 94.81% | |||
| Normalized Basic EPS | 193.45% | 125.50% | |||
| EPS Diluted | 106.22% | 94.81% | |||
| Normalized Diluted EPS | 193.15% | 125.50% | |||
| Average Basic Shares Outstanding | -0.13% | -0.01% | |||
| Average Diluted Shares Outstanding | -0.04% | -0.01% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||